Global Pharmaceutical Pricing and Reimbursement Market Overview, Size, Share and Trends 2018-2026
Summary – A new market study, “Pharmaceutical
Pricing and Reimbursement: Global Markets”has been featured on WiseGuyReports.
Global
healthcare spending is projected to rise to around REDACTED in 2020, with
spending as a percentage of gross domestic product (GDP) flat at around
REDACTED, due to the hostile economic environment and the implementation of
cost constraining measures, including a re-evaluation of the “clinical value”
that products bring to the healthcare ecosystems.
In 2019,
global pharmaceutical sales were estimated to be worth REDACTED and rise by
REDACTED in 2020, as new innovative, expensive cell and gene therapies and
biologics reach the market and the number of originator products at risk of
patent expirations decline. During the first quarter of 2020, most
pharmaceutical companies, such as Bristol-Myers Squibb, GlaxoSmithKline, Eli
Lilly, Johnson & Johnson, and Novartis, witnessed a short-term boost in
sales as wholesalers stockpiled products due to supply chain concerns. Some
areas such as physician or hospital administered medications and travel
vaccines saw a decline in sales, for obvious reasons.
Mergers and
acquisitions (M&A) activity in the pharmaceutical sector keeps ticking
along, with 2019 being one of the most active years in the last decade,
attracting around REDACTED in investment; many transactions involved the
acquisition of cell and gene therapies and immune-oncology assets or to
diversify risks through the adoption of digital technologies and artificial
intelligence (AI).
To contain
healthcare costs, governments across the globe have introduced healthcare
reforms and initiated new legislation and pharmaceutical regulations that look
more closely at the performance and cost-effectiveness of care. The
pharmaceutical regulatory landscape is highly fragmented and divergent, and the
following section summarizes the regulatory processes adopted by the latest top
five European countries and the U.S. However, as regulatory oversight increases
there is a growing need for regulatory harmonization.
Since the
first reports of COVID-19 in Wuhan, China in December 2019, there have been
5,165,481 confirmed cases and over 336,430 confirmed deaths in 216 countries
worldwide, as of May 24, 2020. Relatively few countries remain unscathed by the
pandemic and scientists across the globe have worked together to advise local,
regional and national healthcare organizations to contain the spread of the
disease and develop prophylactic vaccinations and new therapies to treat the
symptoms of the viral infection. Each country has adopted its own healthcare
strategies and mobilized resources based on their individual circumstances, but
only by working together will the world be able to combat this lethal
disease.
More than
$830 million in funding has been pledged to support R&D efforts in
COVID-19, and health tech and pharmaceutical companies are working together in
public-private collaborations, while numerous diagnostics, vaccines and
treatments are already under development and research.
The COVID-19
pandemic has already dramatically changed healthcare delivery, and the economic
impact of COVID-19 pandemic on healthcare spending is unknown. It will depend
on many factors including: level and severity of infection, availability of
diagnostics prophylactic treatments and vaccines, and whether the health system
can manage supply constraints and defer non-essential healthcare
services.Report Scope:
This new
report on pricing and reimbursement in a global market provides a brief
overview on the pharmaceutical markets, healthcare reforms and regulations
across the globe over the last decade and how this has impacted mergers and
acquisitions and venture capitalist investment in the sector. It reviews
pricing and reimbursement policies and processes in the U.S. and Europe and the
ways in which pharmaceutical investment in generics, biosimilars, over the
counter (OTC), small molecule and biological agents; and the shift toward more
innovative medicines such as cell and gene therapies may change future
treatment paradigms and future pricing and reimbursement policies.
Report
Includes:
- An overview
of the global markets for pharmaceuticals, specifically healthcare legislation
and regulation, pricing mechanisms, and reimbursement procedures
- Analyses of
the global market trends, with data corresponding to market size for 2014-2019,
and projections of compound annual growth rates (CAGRs) through 2024
- Information
on the current price and reimbursement landscape, benchmarking statics, and
future development opportunities in the pharma industry
- Case
studies of different price and reimbursement strategies for prescription drugs,
orphan drugs, generics, over-the-counter products, and value-based pricing
- Discussion
on the impact of COVID-19 on pharmaceutical sales in Q1 2020 and overall
healthcare marketplace
- Insight
into the greater adoption of value-based pricing schemes, with emphasis on the
innovative payment models, increased investment in cell and gene therapies, and
long-term response to COVID-19
FOR MORE DETAILS : https://www.wiseguyreports.com/reports/5603109-pharmaceutical-pricing-and-reimbursement-global-markets
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH
TRENT
Ph: +162-825-80070
(US)
Ph: +44 2035002763 (UK)
Comments
Post a Comment